Bone Biologics (OTC:BBLG) Trading Down 6.2% – Time to Sell?

Bone Biologics Co. (OTC:BBLG)’s share price was down 6.2% on Thursday . The company traded as low as $1.20 and last traded at $1.22. Approximately 33,445 shares were traded during mid-day trading, an increase of 2% from the average daily volume of 32,905 shares. The stock had previously closed at $1.30.

Bone Biologics Trading Down 2.2%

The firm has a fifty day simple moving average of $1.67 and a 200-day simple moving average of $1.99. The stock has a market cap of $2.14 million, a price-to-earnings ratio of -0.33 and a beta of 0.75.

Bone Biologics Company Profile

Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBM, an osteopromotive recombinant protein that provides target specific control over bone regeneration. It also develops NELL-1/DBM Fusion Device for use in spinal fusion procedures in skeletally mature patients with spinal degenerative disc disease at one level from L2-S1. The company's platform technology is used in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine.